Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1983 1
1984 1
1985 1
1987 1
1988 2
1989 3
1990 7
1991 2
1992 3
1993 12
1994 9
1995 9
1996 4
1997 6
1998 4
1999 1
2000 3
2001 2
2002 2
2003 3
2004 3
2005 7
2006 7
2007 3
2008 4
2009 7
2010 8
2011 7
2012 6
2013 6
2014 10
2015 14
2016 11
2017 19
2018 13
2019 6
2020 6
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Results by year
Filters applied: . Clear all
Page 1
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. Yu J, et al. Among authors: visscher dw. J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30. J Clin Invest. 2018. PMID: 29708513 Free PMC article.
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. Polley MC, et al. Among authors: visscher dw. Breast Cancer Res Treat. 2021 Feb;185(3):557-566. doi: 10.1007/s10549-020-06030-5. Epub 2021 Jan 3. Breast Cancer Res Treat. 2021. PMID: 33389409 Free PMC article. Review.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Romond EH, et al. Among authors: visscher dw. N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122. N Engl J Med. 2005. PMID: 16236738 Free article. Clinical Trial.
Benign breast disease and the risk of breast cancer.
Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW. Hartmann LC, et al. Among authors: visscher dw. N Engl J Med. 2005 Jul 21;353(3):229-37. doi: 10.1056/NEJMoa044383. N Engl J Med. 2005. PMID: 16034008 Free article.
Neuroendocrine Tumors of the Breast.
Visscher DW, Yasir S. Visscher DW, et al. Endocr Pathol. 2017 Jun;28(2):121-127. doi: 10.1007/s12022-017-9477-4. Endocr Pathol. 2017. PMID: 28389994 Review.
Bronchiolitis: the pathologist's perspective.
Visscher DW, Myers JL. Visscher DW, et al. Proc Am Thorac Soc. 2006;3(1):41-7. doi: 10.1513/pats.200512-124JH. Proc Am Thorac Soc. 2006. PMID: 16493150 Review.
What values are critical?
Visscher DW. Visscher DW. Am J Clin Pathol. 2008 Nov;130(5):681-2. doi: 10.1309/AJCPT10TAXUYAILG. Am J Clin Pathol. 2008. PMID: 18854258 No abstract available.
CHFR and Paclitaxel Sensitivity of Ovarian Cancer.
Wahner Hendrickson AE, Visscher DW, Hou X, Goergen KM, Atkinson HJ, Beito TG, Negron V, Lingle WL, Bruzek AK, Hurley RM, Wagner JM, Flatten KS, Peterson KL, Schneider PA, Larson MC, Maurer MJ, Kalli KR, Oberg AL, Weroha SJ, Kaufmann SH. Wahner Hendrickson AE, et al. Among authors: visscher dw. Cancers (Basel). 2021 Nov 30;13(23):6043. doi: 10.3390/cancers13236043. Cancers (Basel). 2021. PMID: 34885153 Free PMC article.
New frontiers in pathology.
Visscher DW, Myers JL. Visscher DW, et al. Arch Pathol Lab Med. 2009 Nov;133(11):1761-2. doi: 10.5858/133.11.1761. Arch Pathol Lab Med. 2009. PMID: 19886709 Free article. No abstract available.
201 results